Published in Medical Letter on the CDC and FDA, September 14th, 2008
The research says that the Indian pharmaceutical companies hold a very strong competitive advantage in drug manufacturing over their western counterparts in terms of cost of production and reverse engineering skills. The cost of manufacturing both bulk drugs as well as formulations in India is around 10%-20% of the cost it takes in the west. Moreover, many Indian manufacturers have upgraded their manufacturing plants, enabling...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.